Table of Contents Author Guidelines Submit a Manuscript

BioMed Research International has retracted this article. Figures 1(a) and 1(b) show identical gels other than the part of the right-hand lane that includes the band of interest in Figure 1(b).

View the full Retraction here.


  1. C.-Q. Tan, X. Gao, W.-J. Cai, X.-Y. Qian, L. Lu, and H. Huang, “Experimental study of local inner ear gene therapy for controlling autoimmune sensorineural hearing loss,” BioMed Research International, vol. 2014, Article ID 134658, 10 pages, 2014.
BioMed Research International
Volume 2014, Article ID 134658, 10 pages
Research Article

Experimental Study of Local Inner Ear Gene Therapy for Controlling Autoimmune Sensorineural Hearing Loss

1State Key Laboratory of Materials-Oriented Chemical Engineering, College of Biotechnology and Pharmaceutical Engineering, Nanjing University of Technology, No. 5 Xinmofan Road, Nanjing, Jiangsu 210009, China
2Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Jiangsu 210008, China
3Department of Otolaryngology, Affiliated Zhongda Hospital of Southeast University, Nanjing, Jiangsu 210009, China

Received 16 October 2013; Revised 24 January 2014; Accepted 3 March 2014; Published 7 April 2014

Academic Editor: Claus-Peter Richter

Copyright © 2014 Chang-qiang Tan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


This study aimed to investigate the efficacy of gene therapy for treating autoimmune sensorineural hearing loss (ASHL) via local administration of a recombinant adenovirus vector containing the Fas ligand or interleukin IL-10 gene. Guinea pigs were divided into four groups, with different microinjections in the scala tympani. Group A were injected with FasL-EGFP, B with IL-10-EGFP, C with EGFP, and D with artificial perilymph. Seven days later, auditory brain-stem response (ABR) was tested, and the temporal bone was stained and observed by light microscopy. The spiral ligament and basement membrane were observed using transmission electron microscopy. FasL and IL-10 expression were examined using immunofluorescence histochemistry. Immunohistochemical analysis showed that the recombinant adenovirus vector in Groups A, B, and C can transfect the stria vascularis, the spiral ligament, the organ of Corti, the spiral ganglion, the region surrounding the small blood vessel in the modiolus, and the cochlear bone wall. Compared with those in Groups C and D, the ABR wave III mean thresholds were significantly lower and the inner ear immunoinflammatory responses in Groups A and B were significantly alleviated. Inhibition of immunoinflammatory response alleviated immunoinflammatory injury and auditory dysfunction. This technique shows potential as a novel therapy for ASHL.